Celgene Corporation (NASDAQ:CELG) announced that a post-hoc subgroup analysis of a double-blind, placebo-controlled, randomized, multicenter phase II trial of GED-0301 (mongersen) in patients …
In a research report issued April 30, Canaccord Genuity analyst John Newman reiterated a Buy rating on Celgene Corporation (NASDAQ:CELG) with a price target …
In a research report issued Friday, Cantor Fitzgerald analyst Mara Goldstein reiterated a Buy rating on Celgene Corporation (NASDAQ:CELG) with a price target of …
In a research report issued today, Cantor analyst Mara Goldstein reiterated a Buy rating on Celgene Corporation (NASDAQ:CELG) with a price target of …
Celgene Corporation (NASDAQ:CELG) and Quanticel Pharmaceuticals, Inc., a privately held biotechnology company focused on cancer drug discovery, announced a definitive share purchase agreement …
J.P.
Celgene Corporation (NASDAQ:CELG) announced it has fulfilled the accelerated approval requirements for POMALYST® (pomalidomide) based on results from MM-003, an international phase III study …
Celgene Corporation (NASDAQ:CELG) announced that results from a multicenter, randomized, placebo-controlled phase II trial (BCT-001) of apremilast (Otezla®) in patients with Behçet’s disease were …
Celgene Corporation (NASDAQ:CELG) announced the election of Michael W. Bonney to its Board of Directors.
In a research report published Friday, Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating on Celgene Corporation (NASDAQ:CELG) and raised the price …
